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Abstract
Human dendritic cells (DCs) are the main antigen presenting cells (APC) and can be divided into two main populations,
myeloid and plasmacytoid DCs (pDCs), the latter being the main producers of Type I Interferon. The vast majority of pDCs
can be found in lymphoid organs, where the main pool of all immune cells is located, but a minority of pDCs also circulate in
peripheral blood. Human cytomegalovirus (HCMV) employs multiple mechanisms to evade the immune system. In this
study, we could show that pDCs obtained from lymphoid organs (tonsils) (tpDCs) and from blood (bpDCs) are different
subpopulations in humans. Interestingly, these populations react in opposite manner to HCMV-infection. TpDCs were fully
permissive for HCMV. Their IFN-a production and the expression of costimulatory and adhesion molecules were altered after
infection. In contrast, in bpDCs HCMV replication was abrogated and the cells were activated with increased IFN-a
production and upregulation of MHC class I, costimulatory, and adhesion molecules. HCMV-infection of both, tpDCs and
bpDCs, led to a decreased T cell stimulation, probably mediated through a soluble factor produced by HCMV-infected pDCs.
We propose that the HCMV-mediated impairment of tpDCs is a newly discovered mechanism selectively targeting the host’s
major population of pDCs residing in lymphoid organs.
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Introduction
Human cytomegalovirus (HCMV) is a beta-herpesvirus that
persistently infects the host and causes extensive morbidity and
mortality in neonates and immunocompromised patients, includ-
ing transplant recipients. HCMV is highly species-specific, but can
infect a wide range of cell types including endothelial cells and cells
of the hematopoietic system [1–4]. The gene expression follows a
cascade with immediate early (IE) genes coding for regulatory
proteins, early genes (E) coding for e.g. viral polymerases, followed
by late (L) gene expression coding for structural viral proteins.
Synthesis of viral particles is determined at a post entry level, and it
has been shown that cellular and viral factors are responsible for
the completion of the viral replication cycle [5–7]. In non-
permissive cells the replication cycle is usually terminated at the
level of IE and/or E gene expression [8].
Dendritic cells (DC) are potent antigen presenting cells essential
for the initiation of immune responses through priming of naı ¨ve or
resting T cells [9]. In humans, two main DC subsets have been
described; myeloid DCs, which are CD11c
+, CD33
+, CD123
+/2,
and plasmacytoid DCs (pDCs), which are CD11c
2, CD33
2,a n d
CD123
++[10].Thesepopulationsdiffernotonlyintheirphenotypic
marker expression but also in functional properties. Myeloid DCs
can be derived from a CD34
+ hematopoietic progenitor cell and are
strategically located in peripheral tissues at the entry site of
pathogens [11]. After taking up an antigen, they undergo
maturation and activate T cells by direct cell-cell contact and by
the secretion of cytokines. Plasmacytoid DCs and myeloid DCs are
generated in the bone marrow and circulate in peripheral blood in
very low numbers [12]. However the origin of different DC
populations is still a matter of debate. Evidence obtained from the
mouse system indicates that a common myeloid DC/pDC
precursor cell exists, since Del Hoyo et al. demonstrated, that
blood-derived Lin
2CD11c
+MHC-II
2 progenitors differentiate into
spleen CD8
+, CD8
2 DC and pDCs, but not into macrophages,
aftertransferto irradiated mice [13]. Onaietal.alsoidentified a DC
precursor cell in mouse bone marrow that gave rise to myeloid DC
and pDCs, but not to other cell lineages in vitro [14].
However, the vast majority of pDCs can be found in lymphoid
organs such as thymus, bone marrow, spleen, tonsils, and lymph
nodes. After contact with antigen, pDCs migrate directly from the
peripheral blood to the lymphatic tissue using the high endothelial
venules for entry. They are predominantly localized in the T cell
zone of the lymph nodes, where they rapidly produce a large
amount of type I IFN. Here, they activate the innate and adaptive
immune responses [15]. Furthermore, pDCs in tonsils are in close
contact with CD8
+ memory T cells and this colocalization allows
memory CD8
+ T cells to control the pDC response to viruses [16].
In addition, pDCs initiate a productive CD4
+ T cell response in
lymph nodes [17]. Since tpDCs play a key role in the early
regulation of innate and adaptive immunity they are excellent
targets for virus-mediated immune evasion mechanisms.
Viruses that persist in the host have developed multiple strategies
to escape from the attack of the immune system [18,19]. In
particular, HCMV has evolvedseveralmechanisms to modulate the
host response and to escape immune control. These include
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3482blocking of peptide transporters, down-regulation of MHC,
costimulatory and adhesion molecules, expression of MHC class I
homologues, impaired T cell activation, and interference with the
cytokineandchemokinenetwork[20–34].Allthesemechanismsare
used to subvert the inflammatory response during primary HCMV
infection and HCMV reactivation.
In a previous study, we showed that endothelial cell adapted
HCMV strains replicate in myeloid DCs and impair their function
[28]. Recently, Kvale et al. showed that HCMV activate pDCs
isolated from peripheral blood mononuclear cells. They concluded
that this may explain why healthy people experience HCMV
infection and reactivation asymptomatically [35]. In our study we
mainly focus on the major pool of pDCs in the host which resides
in the lymphatic tissue (tpDCs) [36–38]. They are one of the
important key players sitting at the edge of innate and adaptive
immunity in a compartment, which is driving the host immune
response. We demonstrate that tpDCs and bpDCs are different
subpopulations, and that they behave in opposite manner upon
HCMV infection.
Results
BpDCs and tpDCs are two distinct subpopulations
Dendritic cells play a major role in initiating and regulating the
immune response. They share a number of common features, like
MHC class II expression in combination with an absence of the
lineage-specific markers CD3, CD14, and CD19. However, DCs
are a heterogeneous group with variations in their phenotype,
morphology, function, and tissue localization [36,39]. Therefore,
we characterized pDCs isolated from tonsils or blood by flow
cytometry analysis of several surface molecules directly after
isolation (Table 1). Both populations were negative for myeloid
markers (CD11c, CD33), CD45RO (LCA), and CD95 (FAS), and
positive for CD45RA (LCA), the adhesion molecule CD54,
costimulatory molecules (CD80, CD86), the IL-3 receptor
(CD123), and antigen presenting molecules (MHC class I and
MHC class II). They differ in their expression level of the
costimulatory molecule CD40 (tpDC
low; bpDC
2), the adhesion
molecule CD58 (tpDC
2; bpDC
+) and in the expression of NKp44
(tpDC
+; bpDC
2). As described by Fuchs et al. bpDCs upregulate
NKp44 after co-culture with IL-3 in vitro, and crosslinking of
NKp44 leads to inhibition of IFN-a production in response to
cytosine-phosphate-guanosine (CpG) oligonucleotides [16].
Survival of pDCs in cell culture is IL-3 dependent [40]. Thus,
purified tpDCs and bpDCs were re-characterized at day five of
incubation with IL-3 by flow cytometry analysis (Table 1). Both
subpopulations were negative for CD33 and CD95 and positive
for CD45RA, CD54, CD58, CD86, CD123, MHC class I, and
MHC class II. However, they differed in their expression level of
the costimulatory molecules CD40 (tpDC
+; bpDC
2) and CD80
(tpDC
+; bpDC
2), the activation molecule CD45RO (tpDC
+;
bpDC
2) and in the expression of NKp44 (tpDC
2; bpDC
+).
Therefore, we concluded that tpDCs and bpDCs are two distinct
subpopulations.
HCMV productively infects tpDCs only
In a previous study, we and others showed that myeloid DCs
were permissive for HCMV [28]. We investigated whether
endothelial cell-adapted HCMV replicates in tpDCs and bpDCs.
We isolated pDCs from tonsils or blood of healthy HCMV
seronegative donors with a purity of .90%, and characterized the
,10% of contaminating cells obtained from tpDCs and bpDCs.
The small amount of contaminating cells obtained from tpDCs
contained T cells (45–65%), B cells (9–18%), granulocytes (7–12%)
and NK cells (16–20%). In preparations of bpDCs, contaminating
cells comprised T cells (24–35%), B cells (10–15%), granulocytes
(17–40%) and NK cells (20–35%).
Productive HCMV infection of tpDCs and bpDCs was
investigated by confocal two-colour immunofluorescence micros-
copy and shell vial culture. Freshly isolated pDCs were either mock-
infected or infected with HCMV. Since HCMV gene expression
follows a cascade with IE proteins being expressed first, followed by
E and L gene expression, pDCs were analyzed for the expression of
IE protein at day one and L protein (pp150) at day five post
infection using confocal two-colour immunofluorescence microsco-
py. In figure 1, the co-expression of the pDC marker CD123 (IL-
3R) and the viral proteins IE (Fig. 1A) and pp150 (Fig. 1B) are
shown. We demonstrated, that IE as well as pp150 proteins were
present in HCMV-infected tpDCs only, indicating productive
infection. As in non-permissive cells, IE but no late protein (pp150)
was present in bpDCs. Staining for viral proteins in mock-infected
pDCs yielded negative results. The number of HCMV-infected
tpDCs and bpDCs was donor dependent and ranged from 1–10%
(tpDCs) to 0.05–1% (bpDCs), respectively (Table 2).
Productive viral infection was confirmed by shell vial culture
and virus production was measured in supernatants obtained from
infected tpDCs, bpDCs and from virus stocks incubated with
medium only. The latter, to measure virus particle stability under
the same culture conditions. Supernatants of mock-infected pDCs
served as negative controls. As shown in figure 2, HCMV
remained stable in the supernatants up to five days post infection
and could not be detected after day six post infection. Both tpDCs
and bpDCs infected with HCMV showed a decrease in virus
release up to day six post infection. However, after day six post
infection the amount of virus slowly decreased in bpDCs, but
increased in tpDCs. This indicates a short time interval of HCMV
production in tpDCs with only a moderate efficiency. A similar
phenomenon was observed by Riegler et al. when myeloid DC
were investigated [41].
We conclude that tpDCs but not bpDCs were fully permissive
for HCMV since IE and L proteins as well as virus production was
Table 1. Characterization of plasmacytoid DCs.
Cell surface marker tpDC bpDC
Day 0 Day 5 Day 0 Day 5
CD11c 2 low 22
CD33 2222
CD40 low + 22
CD45RA ++++
CD45RO 2 + 22
CD54 low + low +
CD58 2 +++
CD80 ++low 2
CD86 low +++
CD95 2222
CD123 ++ ++ + +
MHC class I ++ + ++ +
MHC class II ++ + ++
NKp44 + 22low/+
Flow cytometry analysis of pDCs was performed directly after isolation (day 0)
and at day five after incubation with IL-3.
doi:10.1371/journal.pone.0003482.t001
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permissive for HCMV, as we only detected IE proteins and failed
to detect virus production by shell vial culture.
HCMV-infection impairs cell surface molecule expression
only in tpDCs
HCMV is able to modulate the expression of antigen
presenting, adhesion, and costimulatory molecules in myeloid
DCs [23,28,42]. We analyzed the ability of HCMV to impair the
expression of key cell surface molecules on pDCs. These include
antigen presenting molecules (MHC class I, MHC class II),
costimulatory molecules (CD40, CD80 and CD86), and adhesion
Figure 1. HCMV protein expression in pDCs analyzed by
confocal two-colour immunofluorescence microscopy. (A) Ex-
pression of HCMV-IE protein (FITC) and CD123 (TRITC) (IL-3R) in HCMV-
infected tpDCs and bpDCs and in mock-infected pDCs at day 1 after
infection. (B) Expression of HCMV late protein pp150 (FITC) and CD123
(TRITC) (IL-3R) in HCMV-infected tpDCs and bpDCs and in mock-
infected pDCs at day five after infection. Bars represent 20 mm.
doi:10.1371/journal.pone.0003482.g001
Table 2. HCMV-infection rates of plasmacytoid DC.
HCMV infection rate [%]
TpDCs BpDCs
Donor 1 10 1
Donor 2 5 1
Donor 3 2,5 0,5
Donor 4 1,5 0,05
Donor 5 10 0,1
Donor 6 1 n.d.
Donor 7 5 n.d.
Donor 8 4 n.d.
TpDCs and bpDCs were stained for HCMV IE protein 18 h after infection.
Infection rates were calculated as the number of IE positive pDCs compared to
IE negative cells. n.d.=not done.
doi:10.1371/journal.pone.0003482.t002
Figure 2. Detection of productive HCMV infection in pDCs.
TpDCs and bpDCs were infected with HCMV. Virus stocks were
incubated with media only. Supernatant of infected tpDCs and bpDCs
and media incubated with HCMV were collected at d1–d9 after
infection and added to uninfected HFFs. Virus titers were measured by
shell vial culture staining for HCMV IE protein expression in HFFs 18 h
post infection.
doi:10.1371/journal.pone.0003482.g002
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expression of CD123 (IL-3 receptor), CD95 (FAS), CD33 (myeloid
marker), CD45RO/RA (LCA) and NKp44 (activation marker of
NK cells). TpDCs and bpDCs were infected with HCMV or left
untreated. As a control, UV-inactivated HCMV was incubated
with tpDCs or bpDCs. UV-inactivated HCMV is unable to infect
cells, but the viral particles are still able to bind to the cell surface
and thus act as antigen stimulus. At day six after infection, the cells
were stained for CD11c, CD33, CD40, CD45RA, CD45RO,
CD54, CD58, CD80, CD86, CD95, CD123, MHC class I, MHC
class II, or NKp44 and analyzed by flow cytometry. The results of
one representative experiment out of five are shown for tpDCs
(Fig. 3A) and for bpDCs (Fig. 3B). Neither mock-infected nor
HCMV-infected tpDCs or bpDCs expressed the cell surface
molecule CD33 or CD95. In HCMV-infected tpDCs the
expression of CD40, and CD45RO was almost completely
downregulated, whereas the expression of CD45RA, CD54,
CD58, CD80, and CD86 was decreased and the upregulation of
CD11c was blocked. No differences in the expression levels of
MHC class I, MHC class II, CD123, or NKp44 were observed. In
contrast, infected bpDCs upregulated the expression of CD40,
CD45RO, CD54, CD58, CD80, MHC class I, and NKp44. The
Figure 3. Kinetics of surface marker expression on tpDCs and bpDCs by flow cytometry analysis. HCMV-infected and mock-infected
tpDCs (A) and bpDCs (B) were stained with anti-human-CD11c-PE, -CD33-FITC, -CD40-FITC, -CD45RA-FITC, -CD45RO-PE, -CD54-FITC, -CD58-PE, -CD80-
FITC, -CD86-PE, -CD95, -CD123-PE, -MHC class I-FITC, -MHC class II-FITC and NKp44-PE at day five after infection. Black lines represent the isotype
controls, red lines the marker expression of mock-infected pDCs, and blue lines the marker expression of HCMV-infected pDCs.
doi:10.1371/journal.pone.0003482.g003
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before nor after infection with HCMV. No differences were
observed when the expression levels of MHC class II, CD123,
CD86, and CD45RA were measured in HCMV-infected or
uninfected bpDCs. Furthermore, there was no difference between
mock-infected pDCs and pDCs incubated with UV-inactivated
HCMV when cell surface molecule expression was analyzed (data
not shown).
We conclude that HCMV was able to impair the expression of
CD45RA, CD45RO, costimulatory and adhesion molecules on
tpDCs but failed to downregulate the expression of antigen
presenting molecules. In contrast, HCMV infection led to an
activation of bpDCs. This resulted in an upregulation of
costimulatory molecules, adhesion molecules, MHC class I and
NKp44.
Infection of tpDCs results in impaired IFN-a production
whereas infection of bpDCs leads to an increased
secretion
The main function of pDCs is the production of the antivirally
active cytokine IFN-a. In previous studies, it was observed that
HCMV was able to inhibit the production of several cytokines in
infected myeloid DCs [28,31,34]. Here, we analyzed the capacity
of tpDCs and bpDCs to produce IFN-a by ELISA using
supernatants of HCMV-infected cells (tpDCs, bpDCs) and cells
stimulated with antigen using UV-inactivated virus five days post
infection. Mock-infected tpDCs and bpDCs served as negative
controls. In figure 4, the mean value of two representative
experiments is given. No IFN-a was detected in supernatants of
mock-infected cells, whereas antigen stimulation with UV-
inactivated HCMV induced cell activation and the production
of IFN-a. In this experimental setting the IFN-a production of
tpDCs was nine fold higher compared to bpDCs (Fig. 4A and
Fig. 4B, white bars), which indicates a higher capacity of tpDC to
produce IFN-a upon stimulation. When the IFN-a production of
HCMV-infected tpDCs (Fig. 4A, black bar) was analyzed, it
turned out that the production of IFN-a was decreased by 10%–
40% compared to tpDCs stimulated with UV-inactivated HCMV
(Fig. 4A, white bar). The decrease of the IFN-a production
correlated with the number of infected cells. A low number of
HCMV-infected tpDCs (1–2.5%) cause an IFN-a suppression of
up to 10%, whereas a high number of infected tpDCs (4–10%)
cause a reduction of the IFN-a production up to 40%. In contrast,
in supernatants of HCMV-infected bpDCs (Fig. 4B, black bar) the
amount of IFN-a was increased up to 20 fold compared to the
IFN-a concentration measured in supernatants of bpDCs
incubated with UV-inactivated HCMV (Fig. 4B, white bar). The
differences in IFN-a production were statistically significant as
measured by chi-square test (p,0.0001).
From these data, we conclude that HCMV selectively impaired
the IFN-a production in tpDCs, whereas HCMV induced the
production of IFN-a in bpDCs.
HCMV-infected tpDCs and bpDCs show decreased ability
to stimulate T cells
The influence of HCMV-infection on T cell stimulation was
investigated by allogeneic mixed lymphocyte reaction (MLR).
TpDCs or bpDCs and T cells from a different donor were co-
cultivated for five days. In this experimental setting the T cells
recognize the foreign MHC molecules and not the antigen
presented by the pDCs. As shown in figure 5, the capacity of
HCMV-infected tpDCs and bpDCs to induce CD4
+ T cell
proliferation was decreased 3–6 fold for tpDCs and 10–20 fold for
bpDCs, when compared to the controls using mock infected cells
or UV-inactivated HCMV. One representative result out of five is
shown for tpDCs (Fig. 5A) and for bpDCs (Fig. 5B). The
3H-
thymidine uptakes are expressed as average cpm of triplicate wells.
The differences in the
3H- thymidine uptakes were statistically
significant as measured by chi-square test (p,0.0001).
Similar results were obtained when the non-adherent fraction of
PBMC were used instead of CD4
+ T cells in the MLR (data not
shown).
In summary, HCMV-infection of both, tpDCs and bpDCs, led
to a decreased allogeneic T cell stimulation. In contrast, UV-
Figure 4. Spontaneous and induced production of IFN-a in tpDCs and bpDCs cultures. Cell culture supernatants from HCMV-infected
pDCs (pDC+HCMV), mock-infected pDCs (pDC mock) and from pDCs incubated with UV-inactivated HCMV (pDC+HCMV UV) were collected five days
post infection. The IFN-a concentration in the supernatants of tpDCs (A) and bpDCs (B) were measured by ELISA.
doi:10.1371/journal.pone.0003482.g004
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Therefore, the binding of HCMV to the cell surface of pDCs
was not driving this effect.
A soluble factor is involved in the impairment of the
allogeneic MLR
In myeloid DCs, a soluble factor induced by IE and/or E genes
has been incriminated in the impairment of T cell activation
[28,32,43]. Since IE gene products were detected in HCMV-
infected tpDCs and bpDCs, we tested the hypothesis that a soluble
factor might be involved in the inhibition of the MLR activity.
UV-inactivated supernatants were obtained from HCMV-infected
tpDCs or bpDCs and transferred to the MLR containing
uninfected pDCs and T cells. The transfer of supernatant induced
a decrease in CD4
+ T cell proliferation when tpDCs (3–6 fold) and
bpDCs (10–20 fold) were used. The inhibition of the MLR using
infected cells or UV-inactivated supernatant transfer yielded
similar results. One representative result out of five is shown for
tpDCs (Fig. 6A) and for bpDCs (Fig. 6B). The
3H-thymidine
uptakes are expressed as average cpm of triplicate wells. The
differences in the
3H- thymidine uptakes were statistically
significant as measured by chi-square test (p,0.0001).
From these results we conclude that a soluble factor produced
by HCMV-infected tpDCs and bpDCs must be involved in the
inhibition of the allogeneic T cell proliferation.
Discussion
Cytomegaloviruses, which persist lifelong in the host, induce a
severe but transient immunosuppression. HCMV-mediated im-
munosuppression can take weeks to months to resolve and has a
critical effect on host survival especially in immunocompromized
subjects [1]. In organ and bone marrow transplant recipients
opportunistic infections may lead to a more severe clinical
outcome as a consequence of HCMV infection. Therefore, it is
crucial to understand the mechanisms involved in HCMV-
mediated immunosuppression. HCMV has evolved several
mechanisms to modulate the host response and to escape immune
control [20–34]. However, the early impairment of APC such as
DCs might play a key role, because the inhibition of the first steps
of the host response supports the viral strategy to disseminate and
build up latency in the host. Plasmacytoid DCs are the main
producer cells of IFN-a and are thought to link innate and
adaptive immunity. Especially cells such as pDCs, which are one
of the key regulators of both innate and adaptive immunity, are
excellent targets, because the impairment of their function
simultaneously hampers both pathways of the immune system.
The host response is even more severely affected when the main
pool of these cells located in the compartments, which are driving
the host immune response, are impaired. To follow this line of
arguments we have investigated pDCs with a focus on pDCs
obtained from lymphatic tissue, where the vast majority of these
cells can be found in the host [15,44]. However, the minority of
pDCs circulating in peripheral blood was also investigated.
First, we characterized pDC populations obtained from
peripheral blood and lymphatic tissue by flow cytometry analysis
of various cell surface markers. It turned out that tpDCs and
bpDCs differed in their expression level of costimulatory molecules
CD40, CD80 (tpDCs
+; bpDCs
2), adhesion molecule CD58
(tpDCs
+; bpDCs
2), activation molecule CD45RO (tpDCs
+;
bpDCs
2), and NKp44 (tpDCs
2; bpDCs
+). Since we found
different cell surface marker expression patterns of bpDCs and
tpDCs directly after isolation and after coculture with IL-3, which
activated the cells and started maturation, we speculate that both
cell populations are closely related but distinct subpopulations.
Microarray analysis data of Lindsted et al. showed that human
bpDCs and tpDCs are very closely related based on the expression
patterns of chemokine receptor, IL receptors, and pattern
Figure 5. HCMV infection suppressed alloreactivity of pDCs in
the MLR. HCMV-infected (MOI 50) pDCs (pDC+HCMV) and pDCs
incubated with UV-inactivated virus (pDC+HCMV-UV) were irradiated
(30 Gray) at day five post infection. 5610
4–5610
2 tpDCs (A) or bpDCs
(B) were added as stimulator cells to 10
5 allogeneic purified CD4
+ T cells
(responder cells). As a control, mock-infected tpDCs or bpDCs (pDC
mock) were included in each experiment. To measure T cell
proliferation, cells were labelled with 1mCi
3H-thymidine per well at
day five after coculture. The incorporation of
3H-thymidine (cpm) was
measured for 18 h.
doi:10.1371/journal.pone.0003482.g005
Plasmacytoid DC and HCMV
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3482recognition receptors. The correlation determined by Lindsted et
al. using hierarchical clustering between tpDCs and bpDCs was
0.91 [45]. The phenotype analysis of Linsted et al. was indeed
different to our analysis, because we investigated in part other cell
surface molecules such as CD33, CD54, CD58, CD95, MHC class
I, and NKp44. Thus, our results are not entirely contradictory.
It is quite obvious that bpDCs and tpDCs are close relatives and
one may speculate that as for many hematopoietic cells the blood
borne bpDCs may be the precursor cells of tpDCs located in the
lymphoid tissues since DCs in lymphoid tissues are in a dynamic
balance, with an estimated half-life of only a few days during
steady-state conditions [46]. This turnover mandates a continuous
replacement of DCs by a precursor population. In the mouse
system there is much evidence that a common precursor cell of
myeloid DC/pDC exists. Del Hoyo et al. demonstrated, that
blood-derived Lin
2CD11c
+MHC-II
2 progenitors differentiate
into spleen CD8
+, CD8
2 DCs and pDCs, but not into
macrophages, after transfer to irradiated mice [13]. Onai et al.
identified also a DC precursor in mouse bone marrow that gave
rise to myeloid DC and pDCs, but not to other cell lineages in vitro
and Naik et al. identified a clonal DC precursor that closely
resembles the common DC precursor [14,47]. It may be fair to
speculate that as for many haematopeitic cells the blood borne
bpDCs might be the precursor cells of tpDCs located in the
lymphoid tissues and that bpDCs can differentiate into tpDCs after
migrating to the lymphoid organs.
However, the main goal of our investigations was to study the
interaction of pDCs with HCMV with a main focus on pDCs
obtained from lymphatic tissue. We looked at HCMV replication in
pDCs and whether the function of these cells was altered as a
consequence of infection. To show viral replication in pDCs, we
applied confocal two-colour immunofluorescence microscopy and
measured virus production by shell vial culture. The complete viral
replication cycle was detected only in tpDCs, whereas in bpDCs the
replication cycle was abrogated before L proteins were expressed.
Low-level viral replication was determined by shell vial culture in
tpDCs only. In contrast to endothelial cells, which replicate HCMV
very efficiently and are known as the main site of viral replication in
the host, tpDCs are only low-level virus producers. As shown here, a
very efficient virus production in tpDCs was not a prerequisite to
switch off their function since the main biological aim, which is to
counteract the first steps of the host immune response, is easily
achieved by low-level virus replication in tpDCs.
In addition, it turned out that in bpDC the virus replication cycle
abrogated before L proteins were expressed. The difference of
bpDCs and tpDCs to support HCMV replication can be explained
bythestageofcelldifferentiationand thepresenceofcertaincellular
factors as shown by an in vitro model of the monocyte/macrophage
system. Here, the presence of certain transcription factors drove
productive HCMV infection; a lack of these factors resulted in a
HCMV restricted gene expression of the IE genes [6,48]. In
addition, we and others have previously shown that HCMV can
infect CD34
+ progenitor cells in the bone marrow, but this infection
was not productive. These progenitor cells serve as a reservoir of
latent virus with limited transcription of viral genes. However,
infectious virus could be recovered only from terminally differen-
tiated cells. The difference between bpDCs and tpDCs in HCMV
replication further supports the hypothesis that these cells belong to
different subpopulations [5,6,8,49].
After we had shown that HCMV can infect bpDCs and tpDCs
but only replicates in tpDCs we investigated whether HCMV
impairs pDC-function. Here, we investigated the cell surface
molecule expression, the production of IFN-a, and the capacity to
stimulate T cells.
Figure 6. HCMV mediated soluble factor suppressed alloreac-
tivity of pDCs in an MLR. HCMV-infected (MOI 50) pDCs
(pDC+HCMV) and pDCs incubated with UV-inactivated supernatant of
HCMV infected pDCs (pDC+UV supernantant) were irradiated (30 Gray)
at day five post infection. 5610
4–5610
2 tpDCs (A) or bpDCs (B) were
added as stimulator cells to 10
5 allogeneic purified CD4
+ T cells
(responder cells). As a control, mock-infected tpDCs or bpDCs (pDC
mock) were included in each experiment. To measure T cell
proliferation, cells were labelled with 1mCi
3H-thymidine per well at
day five after coculture. The incorporation of
3H-thymidine (cpm) was
measured for 18 h.
doi:10.1371/journal.pone.0003482.g006
Plasmacytoid DC and HCMV
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mechanisms to circumvent the host response. One mechanism is
to interfere with the MHC class I pathway in a multistep manner.
As a result of HCMV infection myeloid DCs downregulate the
expression of MHC- class I, which impairs antigen presentation
[28]. Surprisingly, MHC class I molecule expression in HCMV-
infected tpDCs and bpDCs was not altered. The molecular
mechanism responsible for this difference still remains to be
elucidated. However, there was a clear difference in the marker
profile expression when HCMV-infected bpDCs and tpDCs were
compared. BpDCs were simply activated which resulted in an
increased expression of all key cell surface molecules such as
antigen presenting molecules, adhesion molecules and costimula-
tory molecules. In HCMV-infected tpDCs however, a downreg-
ulation of adhesion and costimulatory molecules was observed,
whereas no impairment of antigen presenting molecules occured.
This might not be due to the fact that only up to 10% of these cells
are infected because a HCMV-mediated downregulation of
adhesion and costimulatory molecules occurred in all cells
analyzed by flow cytometry. Thus, HCMV-mediated downregu-
lation of cell surface markers does not occur in infected cells only.
This represents first evidence, that, as described for myeloid DCs,
a soluble factor may be involved [28,32,43]. The decrease of key
molecules on tpDCs is the first evidence that the function of the
main pool of pDCs, and thus the lymphatic tissue of the host, is
impaired as a consequence of HCMV infection.
The main function of pDCs is the production of IFN-a and it is
well known that in response to certain viruses, like cytomegalo-
viruses, pDCs produce high amounts of IFN-a [50,51], which is
important for the first line of antiviral host response. The
disruption of IFN-a signalling in IFNR-ab knockout mice, for
example, rendered them highly susceptible to mouse cytomega-
lovirus infection [52]. In the study presented here, HCMV
infection of bpDCs resulted in stimulation of IFN-a production
compared to uninfected controls. These data are in accordance
with Kvale et al. and Varani et al., who focussed exclusively on
bpDCs and myeloid DCs from peripheral blood [35,53].
Interestingly, the capacity of the IFN-a production after
stimulation with antigen was nine fold lower in bpDCs compared
to tpDCs. This also supports the hypothesis that bpDCs could be
precursor cells of tpDCs, since immature precursor cells might not
have yet gained full functional activity and fail to produce high
amounts of IFN-a. On the other hand HCMV-infection impaired
the production of IFN-a in tpDCs, but failed to suppress IFN-a
production in bpDCs. A possible explanation is that this effect
strictly depends on the number of cells infected. Small number of
infected tpDCs (1–2.5%) led to a reduction of only 10% whereas a
high number of infected tpDCs (up to 10%) induced a decrease of
IFN-a production up to 40%. Since the numbers of infected
bpDCs is up to 20fold lower compared to tpDCs no suppression of
the IFN-a production was observed. In summary, the production
of IFN-a was altered in tpDCs but not in bpDCs as a consequence
of HCMV infection in vitro. This might have an impact on the
function of the lymphatic tissue during HCMV infection.
However, the situation in vivo remains to be elucidated.
Another key function of DCs is the induction of a T cell
response. Thus, we investigated this issue using pDCs from blood
and tonsils. Our data are in accordance with Varani et al. who
could show that HCMV hamper the allostimulatory ability of
bpDCs [53]. In addition, we could show an impairment of the
MLR in tpDCs. This indicates that in HCMV infection T cell
stimulation might be impaired in the lymphatic tissue. Since T cell
stimulation of both, bpDCs and tpDCs, was affected the
expression of IE genes was sufficient to achieve this effect. It is
known that myeloid DCs are more powerful inducers of a T cell
response compared to pDCs. Thus, the proliferation rate using
pDCs was lower as previously observed for myeloid DCs [28,54].
However, the transfer of UV-inactivated supernatants obtained
from HCMV-infected pDCs to uninfected pDCs prior to
allogeneic T cell stimulation also caused a severe impairment of
the MLR. This clearly shows that, as in myeloid DCs, a soluble
inhibitory factor was involved in the T cell impairment [28,32,43].
It could be argued that cross-presentation of DCs might be a
mechanism to bypass HCMV-induced immunosuppression, since
early NK cell killing of HCMV-infected cells can induce antigen
presentation very early on in non-infected DCs [55]. A
countermeasure to the effect of cross-presentation is the produc-
tion of the soluble factor which induces inhibition of T cell
proliferation in pDCs as shown here and as described previously
for myeloid DC [28,32,43]. Furthermore, Benedict et al. have
shown very recently that murine cytomegalovirus programs
infected DCs during acute infection to inhibit the T cell response
of the host by tipping the balance between negative and positive
cosignals [56]. The relevance of the different steps in the
impairment of HCMV-mediated T cell function still remains to
be defined.
In summary, we could show that based on the expression of cell
surface markers human pDCs obtained from peripheral blood and
from lymphatic tissue are two distinct subpopulations, which also
differ in their capability to permit replication and production of
HCMV. TpDCs could be productively infected with HCMV and
this led to a severe impairment of cell function including a reduced
IFN-a production and a downregulation of costimulatory,
adhesion, and activation molecules. In contrast, the abrogated
replication of HCMV in bpDCs resulted in cell activation with an
upregulation of several surface molecules and a stimulation of
IFN-a production. Interestingly, in both populations an HCMV-
mediated soluble factor was involved in the impairment of T cell
stimulation. The almost selective impairment of pDC function in
lymphoid organs, targets the main pool of these cells in the
compartment where the host generates the immune response. This
is a new immune evasion mechanism employed by HCMV.
Materials and Methods
Viruses
Clinical HCMV strains were kindly provided from Ch. Sinzger
(Institut fuer medizinische Virologie, Tuebingen, Germany). The
following endothelial cell adapted virus stocks were used: AA07/E,
KSA16/3, TB40/E, TB42/E. Virus stocks were grown on
endothelial cells and generated by ultracentrifugation as described
previously [28].
Preparation of plasmacytoid DCs
TpDCs were isolated from tonsils of healthy, HCMV seroneg-
ative humans. This was approved by the ethic committee of the
university hospital of Freiburg (for details refer to: http://www.
uniklinik-freiburg.de/ethik-kommission/live/index.html) and tissue
samples were onlyinvestigatedat theuniversityhospital ofFreiburg.
Informed verbal and written consent was obtained from all patients.
Tonsillectomy was performed at the department of otorhinolaryn-
gology head and neck surgery, university hospital Freiburg,
Germany. Fresh tonsils were cut into small fragments and added
to RPMI 1640 (CCpro, Neustadt an der Weinstrasse, Germany)
supplemented with 1 mg/ml Collagenase and 0.25 mg/ml DNAse
(Roche Diagnostics, Wiesbaden, Germany). After incubation
(40 min, 37uC) the suspension was pushed through a nylon mesh
(70 mm), resuspended in PBS containing 2% FCS and separated by
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tpDCs the interphase cells were collected and purified using the
depletion step of the Blood Dendritic Cell Isolation Kit I (Miltenyi
Biotec,BergischGladbach,Germany)followedbytheBDCA-4 Cell
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany).
BpDCs were isolated from buffy coats of healthy, HCMV
seronegative donors. Buffy coats were obtained commercially from
the department of transfusion medicine, university hospital
Freiburg, Germany. The use of buffy coats for research purposes
was approved by the ethics committee of the university hospital of
Freiburg (http://www.uniklinik-freiburg.de/ethik-kommission/
live/index.html). Prior blood donation informed written consent
was obtained. Peripheral blood mononuclear cells were isolated by
Ficoll gradient (Pharmacia, Upsalla, Sweden). For enrichment of
bpDCs, the interphase cells were collected and purified using the
same protocol as for tpDCs. TpDCs and bpDCs were placed in
culture using RPMI 1640, 10% FCS and 2 mM glutamine
supplemented with IL-3 (10 ng/ml, R+D Systems, Wiesbaden,
Germany).
Infection of plasmacytoid DCs
For all experiments pDCs were infected with an MOI of 50
from a pool of equal amounts of different purified HCMV strains.
The pDCs were incubated for 24 h with infectious supernatant,
washed, and placed in culture.
HCMV infection rates were measured by shell vial culture as
described previously [28] using immunoflourescence staining for
HCMV IE protein expression 18 h post infection on HFF.
To calculate HCMV virus titers in infected pDCs, supernatants
of HCMV infected tpDCs and bpDCs were collected between day
one and day nine after infection. These supernatants were diluted
between 10 fold to 10
6 fold in tissue culture medium and added to
uninfected HFFs. Total amount of HCMV IE positive HFFs were
counted 18 hours post infection. The virus titers were then
calculated by the dilution factor and the number of HCMV IE
positive cells.
Confocal immunofluorescence microscopy
To perform a two-colour immunofluorescence staining, pDCs
were harvested at day one (detection of HCMV IE protein) and at
day five after infection (detection of HCMV pp150 protein). The
cells were first incubated with CD123-Biotin (BD Pharmigen,
Heidelberg, Germany) followed by Streptavidin-Alexa546 (Mo-
lecular probes, Leiden, Netherlands). The cells were fixed and
permeabilized in acetone/methanol. After incubation with anti-
HCMV-IE (Biosoft,Varilhes, France) or anti-HCMV-pp150
(MAK CMV pxp1 a kind gift from Dr. Walter, Behring, Marburg,
Germany), an anti-mouse-IgG1-FITC antibody was used to detect
IE and pp150 expression (BD Pharmingen, Heidelberg, Ger-
many). The slides were analysed with a confocal microscope (DM
IRBE, Leica, Wetzlar, Germany).
Flow cytometry analysis
Infected and mock-infected pDCs were collected at day five
after infection, washed and incubated with one or two of the
following monoclonal Antibodies: anti-CD11c-PE (S-HCL-3, BD
Pharmingen, Heidelberg, Germany), anti-CD33-FITC (D3HL60-
251, Dianova, Hamburg, Germany), anti-CD40-FITC (5C3, BD
Pharmingen), anti-CD45-RA-FITC (HI100, BD Pharmingen),
anti-CD45-RO-PE (UCHL1, BD Pharmingen), anti-CD54-FITC
(84H10, Immunotech, Marseille, France), anti-CD58-PE
(AICD58, Immunotech), anti-CD80-FITC (BB1, BD Pharmin-
gen), anti-CD86-PE (IT2.2, BD Pharmingen), anti-CD95-FITC
(DX2, BD Pharmingen) anti-CD123-PE (9F5, BD Pharmingen),
anti-MHC class I-FITC (G46-2.6, BD Pharmingen), anti-MHC
class II-FITC (Tu ¨39, BD Pharmingen), anti-NKp44-PE (Z231,
Beckman Coulter, Marseille, France). The samples were analyzed
on a FACSsort
TM (Becton Dickinson, Heidelberg, Germany) using
the CellQuest Pro
TM software.
Cytokine detection
Production of IFN-a was measured in culture supernatants
using commercially available ELISA-kits (human IFN-a Module
Set, Bender MedSystems, Vienna, Austria) according to the
manufacturers recommendations. Supernatants of mock-infected,
HCMV-infected and with UV-inactivated HCMV strains incu-
bated pDCs were measured. Cytokines were determined at day six
after infection.
Allogeneic mixed lymphocyte reaction
HCMV-infected (MOI 50) and mock-infected pDCs were
irradiated (30 Gray) at day five post infection. Different numbers
of pDCs (5610
4–5610
2) were added to 10
5 allogeneic purified
CD4
+ T cells (isolated with the CD4
+ T cell isolation kit (Miltenyi
Biotec, Bergisch Gladbach, Germany)) or PBL per well. To
measure T cell proliferation, cells were labelled with 1mCi
3H-
thymidine (Pharmacia, Uppsala, Sweden) per well at day five after
coculture, incubated for 18 h, harvested on filters and counted
with a Trace-96b-Counter (Berthold, Wildbad, Germany). Each
experiment was done in triplicate and was performed using
infected, mock-infected and UV-light inactivated virus stocks. In
the transfer experiment settings, 50 ml of UV-inactivated super-
natant obtained from uninfected or HCMV-infected pDCs was
added.
Statistical analysis
A chi-square test was applied to analyze differences in IFN-a-
production and
3H-thymidine uptakes by contingency tables using
GraphPad Prism 4.0.
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